Market news

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.

Recent performance swings in ADMA Biologics (ADMA) have put fresh attention on what investors are paying for its plasma-derived therapies business after a year of sharp declines and a much stronger past 3 months. The recent rebound in ADMA Biologics, with a 12.07% 90‑day share price return, contrasts sharply with a year‑to‑date share price decline of 47.54%, while a very large 5‑year total shareholder return of about 7x signals that long‑term holders have seen substantial gains. Scan beyond...

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ADMA Biologics stock is downgraded to Hold as FY26 guidance drops and growth slows. See ADMA's ASCENIV outlook, BIVIGAM decline, and $9.52 DCF.

Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressure weighs on Bivigam sales.

ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Read more on what could be next for this biotech.

Detailed price information for Adma Biologics (ADMA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Adma Biologics (ADMA-Q) from The Globe and Mail including charting and trades.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year 2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year 2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year 2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Yea

ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.

Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report second quarter 2026 financial results on August 5, 2026, after the U.S. financial markets close. ADMA’s management team will host a li

In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day.

The latest trading day saw Adma Biologics (ADMA) settling at $8.59, representing a -1.83% change from its previous close.

Detailed price information for Adma Biologics (ADMA-Q) from The Globe and Mail including charting and trades.

Multiple securities class action lawsuits have been filed against ADMA Biologics (NasdaqGM:ADMA) following allegations of channel stuffing and misleading revenue recognition. Regulatory and internal investigations are underway into the company’s revenue practices, internal controls, and undisclosed related party transactions. The volume and scope of these legal actions introduce material questions around ADMA Biologics’ financial reporting and governance practices. ADMA Biologics operates...

Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

The latest trading day saw Adma Biologics (ADMA) settling at $9.16, representing a +2.35% change from its previous close.